Co-blocking TIGIT and PVRIG using a novel bispecific antibody enhances anti-tumor immunity.
Sign Up to like & getrecommendations! Published in 2025 at "Molecular cancer therapeutics"
DOI: 10.1158/1535-7163.mct-23-0614
Abstract: TIGIT and PVRIG are immune checkpoints co-expressed on activated T and NK cells, contributing to tumor immune evasion. Simultaneous blockade of these pathways may enhance therapeutic efficacy, positioning them as promising dual targets for cancer… read more here.
Keywords: pvrig; bispecific antibody; tigit pvrig; anti tumor ... See more keywords
Abstract 593: Bispecific antibody against TIGIT and PVRIG enhances antitumor immunity
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-593
Abstract: T cell immunoreceptor with Ig and ITIM domains (TIGIT) and poliovirus receptor-related immunoglobulin domain-containing protein (PVRIG) are two immune checkpoint receptors. They compete with CD226 for binding to CD155 or CD112 and suppress the activity… read more here.
Keywords: antibody tigit; bispecific antibody; pvrig enhances; tigit pvrig ... See more keywords
Abstract 3219: Assessing strategies to activate DNAM1 signaling and inhibit the TIGIT/PVRIG axis using mathematical modeling
Sign Up to like & getrecommendations! Published in 2025 at "Cancer Research"
DOI: 10.1158/1538-7445.am2025-3219
Abstract: PVR (CD155) and CD112 are ligands from the Nectin/Nectin-like family, frequently expressed on various tumor cells. PVR binds to the inhibitory receptors TIGIT and CD96, triggering a direct inhibitory signal in T and NK cells,… read more here.
Keywords: dnam1; pvrig; pvr; tigit pvrig ... See more keywords
Abstract 7301: FP011, A tri-specific immune checkpoint inhibitor targeting PD-1 × TIGIT × PVRIG for cancer immunotherapy
Sign Up to like & getrecommendations! Published in 2025 at "Cancer Research"
DOI: 10.1158/1538-7445.am2025-7301
Abstract: Immune checkpoint inhibitors, such as anti-PD-1/PD-L1 antibodies, have rapidly changed the treatment paradigm for multiple tumor types. Unfortunately, many patients still remain unresponsive or acquire resistance after initial response to treatment. The complex network of… read more here.
Keywords: cancer; fp011; pvrig; tumor ... See more keywords
Abstract CT168: Phase I study of COM701 (a novel checkpoint inhibitor of PVRIG) in patients with advanced solid tumors
Sign Up to like & getrecommendations! Published in 2019 at "Cancer Research"
DOI: 10.1158/1538-7445.sabcs18-ct168
Abstract: Background: A high unmet medical need exists for the treatment of patients who are unresponsive to or relapse following treatment with checkpoint inhibitors. Therefore, novel checkpoint inhibitors that can demonstrate clinical activity in this patient… read more here.
Keywords: advanced solid; novel checkpoint; study; solid tumors ... See more keywords
PVRL2 Suppresses Antitumor Immunity through PVRIG- and TIGIT-independent Pathways
Sign Up to like & getrecommendations! Published in 2024 at "Cancer Immunology Research"
DOI: 10.1158/2326-6066.cir-23-0722
Abstract: PVRL2 is believed to act as an immune checkpoint protein in cancer; however, most insight into PVRL2’s role is inferred from studies on its known receptor PVRIG. Here, we directly study PVRL2. PVRL2 levels are… read more here.
Keywords: deletion; cancer; effect; pvrig ... See more keywords
Phase I safety and preliminary efficacy of PM1009, a bispecific antibody targeting TIGIT and PVRIG, in patients with advanced solid tumors.
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.16_suppl.e14695
Abstract: e14695 Background: PM1009 is an anti-TIGIT x PVRIG bispecific antibody containing a fully human anti-TIGIT IgG1 fused with a fully human anti-PVRIG scFv at the C terminus. PM1009 can potently block the TIGIT/CD155/CD112 and PVRIG/CD112… read more here.
Keywords: bispecific antibody; pm1009; pvrig; occurred patients ... See more keywords
PVRIG is a novel NK cell immune checkpoint receptor in acute myeloid leukemia.
Sign Up to like & getrecommendations! Published in 2020 at "Haematologica"
DOI: 10.3324/haematol.2020.258574
Abstract: This study explored the novel immune checkpoint poliovirus receptor-related immunoglobulin domain-containing (PVRIG) in acute myeloid leukemia (AML). We showed that AML patient blasts consistently expressed the PVRIG ligand (poliovirus receptor-related 2, PVRL2). Furthermore, PVRIG blockade… read more here.
Keywords: immune checkpoint; pvrig; acute myeloid; receptor ... See more keywords